TheraRadar

Intarcia

Pre-Approval PRO BETA

Inactive Company

No clinical trial activity in 3+ years. This company may have been acquired, shut down, or pivoted away from clinical development. Last trial started: 3/3/2017

15
Total Trials
9
Phase 3
1
Phase 2
0
Recruiting
158
Score

Pipeline by Phase

Phase 3
9
Phase 2
1
Phase 1
5

Therapeutic Focus

Type 2 Diabetes Diabetes Mellitus, Type 2 Healthy Adult Male and Female Volunteers Healthy Renal Insufficiency

Clinical Trials (15)

NCT03060980 Phase 3 TERMINATED

Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

Started: 3/3/2017

NCT01785771 Phase 3 TERMINATED

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

Started: 5/1/2013

NCT02638805 Phase 3 COMPLETED

Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

Started: 12/1/2015

NCT01455896 Phase 3 COMPLETED

A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650

Started: 3/1/2013

NCT01455870 Phase 3 COMPLETED

A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

Started: 5/1/2013

NCT01455857 Phase 3 COMPLETED

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes

Started: 3/1/2013

NCT01455883 Phase 3 WITHDRAWN

A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes

Started: 2/1/2013

NCT01455909 Phase 3 WITHDRAWN

A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes

Started: 2/1/2013

NCT01455922 Phase 3 WITHDRAWN

A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes

Started: 2/1/2013

NCT00943917 Phase 2 COMPLETED

Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus

Started: 8/1/2009

NCT02650479 Phase 1 COMPLETED

Study of the Effects of Intravenous Exenatide on Cardiac Repolarization

Started: 1/1/2016

NCT02641899 Phase 1 COMPLETED

Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs

Started: 12/1/2015

NCT02320045 Phase 1 COMPLETED

Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal Subjects

Started: 11/1/2014

NCT02641990 Phase 1 COMPLETED

Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects

Started: 12/1/2015

NCT01798264 Phase 1 COMPLETED

Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes

Started: 2/1/2009

Drug Candidates

ITCA 650 20/60 mcg/day Empagliflozin (oral) Glimepiride (oral) ITCA 650 (exenatide in DUROS) ITCA 650 Osmotic Mini Pump 20/60 mcg/day ITCA 650 Osmotic Mini Pump 60 mcg/day Metformin Liraglutide Exenatide Placebo
Activity Status: Inactive
Last Trial Started: 3/3/2017
Last Trial Ended: 1/26/2018
Trials (12 months): 0
Completed Trials: 10
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.